| Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 41.87 | -12.99 | 1.56 | -0.28 |
Op profit growth | 164.29 | -33.64 | 123.17 | -22.6 |
EBIT growth | 395.89 | -56.69 | 63.14 | -70.99 |
Net profit growth | -605.74 | -289.45 | -105.74 | -339.34 |
Profitability ratios (%) | ||||
OPM | 18.69 | 10.03 | 13.15 | 5.98 |
EBIT margin | 13.91 | 3.98 | 7.99 | 4.97 |
Net profit margin | 9.7 | -2.72 | 1.25 | -22.12 |
RoCE | 9.25 | 1.81 | 4.48 | 2.82 |
RoNW | 2.25 | -0.42 | 0.27 | -5.48 |
RoA | 1.61 | -0.31 | 0.17 | -3.13 |
Per share ratios (₹) | ||||
EPS | 10.46 | -0.74 | 1.21 | 0 |
Dividend per share | 0 | 0 | 0 | 0 |
Cash EPS | 3.36 | -5.3 | -3.09 | -24.06 |
Book value per share | 81.83 | 81.06 | 88.23 | 78.31 |
Valuation ratios | ||||
P/E | 27.76 | -268.91 | 104.17 | 0 |
P/CEPS | 86.22 | -37.52 | -40.7 | -5.12 |
P/B | 3.54 | 2.45 | 1.42 | 1.57 |
EV/EBIDTA | 20.76 | 35.78 | 16.37 | 17.47 |
Payout (%) | ||||
Dividend payout | 0 | 0 | 0 | 0 |
Tax payout | -30.5 | 1,816.62 | -89.42 | 73.68 |
Liquidity ratios | ||||
Debtor days | 30.95 | 41.5 | 36.59 | 37.73 |
Inventory days | 6.37 | 7.01 | 5.7 | 5.12 |
Creditor days | -51.43 | -62.14 | -66.46 | -60.91 |
Leverage ratios | ||||
Interest coverage | -5.41 | -0.96 | -1.8 | -0.88 |
Net debt / equity | 0.13 | 0.18 | 0.19 | 0.42 |
Net debt / op. profit | 0.78 | 2.75 | 2.17 | 6.38 |
Cost breakup (₹) | ||||
Material costs | -23.73 | -24.21 | -20.8 | -21.9 |
Employee costs | -17.01 | -21.06 | -19.77 | -19.85 |
Other costs | -40.54 | -44.68 | -46.26 | -52.24 |
Fortis will take charge of the entire operational and financial aspects. Hence, consolidating the hospital's performance within its network.
Operating performance remained strong with EBITDA rising 43% year-on-year to ₹490.4 crore. The EBITDA margin expanded to 22.6%, from 18.4% a year ago.
The tax demand will not affect the company’s financials or operations, it said in a regulatory filing.
Here are some of the stocks that may see significant price movement today: UltraTech Cement, Jio Financial, Avenue Supermarts, etc.
EBITDA grew 32.1% YoY at ₹375.2 crore v/s ₹284 crore, a period to period, as was the expansion of EBITDA margin at 19.5% versus 16.9% Q3 FY24.
The deal worth ₹429.37 crore involves acquiring 5,970,149 equity shares at an agreed price of ₹719.2 per share through a shareholders' agreement.
Revenue from operations saw a notable growth of 12.3%, reaching ₹1,988.4 Crore, compared to ₹1,770 Crore YoY.
Jacob Ballas and International Finance Corporation (IFC), who together with Resurgence PE own approximately 34% of the diagnostics company.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
